Overkill, dilution call it whatever you like. Im in for the long...

Overkill, dilution call it whatever you like. Im in for the long run as STI has huge potential and a number of projects/ products in the pipeline which take time to bring online, namely the HDA. Who cares if the current SPP dilutes the company shareholding when the potential for Multi-Bill revenue is staring us in the face with the HDA.

Patience people. I cant think of any other health spec that started from scratch and became great in one day.

Just remember, the current management has been at the helm for approx 2 years and in that time the (1) Canada plant was picked up at a 20M bargain following the GFC (NTA alone is greater than the current SP)- hence manufacturing for STI/ 3rd party products to begin shortly, (2) the HDA development is progressing on schedule (working prototype already developed and scheduled for delivery to potential customers to test & tweek), (3) Telemedcare acquisition will provide STI with a 20% cut of profits in the first two years, and 40% thereafter. (4) Dont forget Immunoxel - one for the bottom drawer.

Patience...wise move to load up on 0.005 levels, investors wont be disappointed this time 2012.